Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

60.0%

3 terminated/withdrawn out of 5 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A
5(100.0%)
5Total
N/A(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05052684Not ApplicableTerminated

The Leaflex™ Brazilian Standalone Study

Role: lead

NCT06211296Not ApplicableCompleted

The ShortCut™ Continued Access Study Protocol

Role: lead

NCT04636073Not ApplicableWithdrawn

The Leaflex™ Early Feasibility Study

Role: lead

NCT04649099Not ApplicableTerminated

The Leaflex™ Standalone Study Protocol

Role: lead

NCT04952909Not ApplicableCompleted

The ShortCut™ Study Protocol

Role: lead

All 5 trials loaded